

Oxurion Receives Transparency Notifications

Leuven, BELGIUM, Boston, MA, US – February 10, 2022 – 7.30 PM CET [Oxurion NV](#) (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation¹ it has received a transparency notification as follows:

Oxurion received a transparency notification on February 9, 2023 from Negma Group Ltd. indicating that as of February 3, 2023, it held 12,528,163 shares of the then outstanding 466,875,130 shares, and therefore crossed below the threshold (3%) by virtue of disposal of voting securities. See Annex 1

Oxurion received a transparency notification on February 8, 2023 from Negma Group Ltd. indicating that as of February 1, 2023, it held 17,693,115 shares of the then outstanding 466,875,130 shares, and therefore crossed below the threshold (5%) by virtue of disposal of voting securities. See Annex 2

In addition, Oxurion informs the markets that it has updated the Transparency Notifications section of its investor relations website (<https://ir.oxurion.com/shareholder-information/transparency-notifications>) to incorporate additional transparency notifications from Negma, Thomas M. Clay/Epacria Capital Partners LLC and Philippe Vlerick/Bareldam SA disclosing their positions having crossed below the threshold (3%) by virtue of the issuance of new voting securities in late 2022.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is a biopharmaceutical company developing next generation standard of care ophthalmic therapies, which are designed to improve and better preserve vision in patients with retinal disorders including diabetic macular edema (DME), the leading cause of vision loss in working-age people, as well as other conditions. Oxurion intends to play an important role in the treatment of retinal disorders, including the successful development of THR-149, its novel therapeutic for the treatment of DME. THR-149 is a potent plasma kallikrein inhibitor being developed as a potential new standard of care for the up to 50% of DME patients showing suboptimal response to anti-VEGF therapy. Oxurion is headquartered in Leuven, Belgium, with corporate operations in Boston, MA. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered “forward-looking”. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company’s Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any

applicable U.S. state securities laws.

For further information please contact:

<p><u>Oxurion NV</u> Tom Graney Chief Executive Officer Tel: +32 16 75 13 10</p> <p>" tom.graney@oxurion.com</p> <p>Michael Dillen Chief Business Officer Tel: +32 16 75 13 10 michael.dillen@oxurion.com</p>	<p><u>US</u> <u>Conway Communications</u> Mary T. Conway mtconway@conwaycommsir.com</p> <p><u>ICR Westwicke</u> Christopher Brinzey Tel: +1 617 835 9304 Chris.Brinzey@westwicke.com</p>
---	---

1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights
Downward crossing of the lowest threshold

-
+

4) Notification by

A parent undertaking or a controlling person

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Elaf Gassam	
Negma Group Investment Ltd.	Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai (United Arab Emirates)
Negma Group Ltd.	Craigmuir chambers, Road Town, Tortola, VG 1110 (British Virgin Islands)

-
-
+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

03/02/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3


 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

7) Date on which the threshold is crossed

03/02/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

3

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

466,875,130

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights	# of voting rights		% of voting rights
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Elaf Gassam	0	0		0.00%	
Negma Group Investment Ltd.	0	0		0.00%	
Negma Group Ltd.	17,693,115	12,528,163		2.68%	
Subtotal	17,693,115	12,528,163		2.68%	


-
-
-
+



TOTAL	12,528,163		2.68%	
-------	------------	--	-------	--

 Start with "groups" of holders. Add subtotals with , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction						
	Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
							+
TOTAL							

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	CALCULATE	12,528,163 2.68%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Negma Group Ltd. is controlled by Negma Group Investment Ltd. (Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai, UAE - Company number: CL5377), who in its turn is controlled by Elaf Gassam (private individual).

12) In case of proxy voting for only one GM


Holder will cease to hold / will hold again 0 voting rights as of (DD/MM/YYYY)

13) Additional information

Done at Dubai, United Arab Emirates

On 09/02/2023 (DD/MM/YYYY)

Name & capacity Elaf Gassam, Director

Signature 

ANNEX 2

 FSMA FINANCIAL SERVICES AND MARKETS AUTHORITY	Transparency notification Form TR-1 BE PART I
--	--

1) Status of the notification

Final

2) Issuer

Name OXURION
Identification number 0881-620-924

3) Reason for the notification

Acquisition or disposal of voting securities or voting rights

+

4) Notification by

A parent undertaking or a controlling person

+

5) Persons subject to the notification requirement

Name	Address (for legal entities)
Elaf Gassam	
Negma Group Investment Ltd.	Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai (United Arab Emirates)
Negma Group Ltd.	Craigmuir chambers, Road Town, Tortola, VG 1110 (British Virgin Islands)

-

-

+

6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)

Name	Address (for legal entities)

+

 Please continue entering the information in **part II** concerning the persons referred to in Sections 5 and 6


Part II

7) Date on which the threshold is crossed

01/02/2023 (DD/MM/YYYY)

8) Threshold that is crossed (in %)

5

 If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10

9) Denominator

466,875,130

 Please enter the denominator before filling in the data

10) Notified details

A) Voting rights	Previous notification	After the transaction			
		# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Elaf Gassam	0	0		0.00%	
Negma Group Investment Ltd.	0	0		0.00%	
Negma Group Ltd.	46,068,257	17,693,115		3.79%	
Subtotal	46,068,257	17,693,115		3.79%	

-
-
-
+



TOTAL	17,693,115	0	3.79%	0.00%
-------	------------	---	-------	-------

Start with "groups" of holders. Add subtotals with Σ , and then finish with the persons who are "alone".
For groups, start with the ultimate controlling natural person or legal entity.
The totals, subtotals and % will be updated once you have clicked on <CALCULATE>.

B) Equivalent financial instruments	After the transaction					
Holders of equivalent financial instruments	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
TOTAL				0	0.00%	

 The totals will be updated once you have clicked on <CALCULATE>

TOTAL (A & B)	# of voting rights	% of voting rights
	17,693,115	3.79%

CALCULATE

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

Negma Group Ltd. is controlled by Negma Group Investment Ltd. (Unit 1 Level 28, ICD Brookfield Place, DIFC, Dubai, UAE - Company number: CL5377), who in its turn is controlled by Elaf Gassam (private individual).

12) In case of proxy voting for only one GM

Holder will cease to hold / will hold again voting rights as of (DD/MM/YYYY)

13) Additional information

Done at Dubai, United Arab Emirates

On 07/02/2023 (DD/MM/YYYY)

Name & capacity Elaf Gassam, Director

Signature